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Abstract Toxoplasmosis is the most common cause
of posterior uveitis in the world. This study described
the clinical characteristics and visual outcome of 193
patients with ocular toxoplasmosis at Feiz Hospital
(Isfahan, Iran) during the last six years. The setting
and design used was a retrospective non-comparative
observational case series. In this study, 193 patients
with ocular toxoplasmosis (111 female, 82 male) were
enrolled. The distribution of symptoms and fundo-
scopic findings were studied. The most-reported chief
complaint was blurred vision in 96 % (184 patients)
and floaters in 13.47 % (25 patients) of cases and most
frequent clinical manifestations were chorioretinitis
98.48 % (190 patients), macular scars 50.7 % (98
patients), and atrophic optic papilla two (1.03 %)
patients. Primary retinal lesions were observed in 16
(8.2 %) and combination of active lesions and old
retinochoroidal scars in 177 (91.7 %) of the patients.
Retinal detachment occurred in 11 (5.69 %) patients.
Bilateral involvement was found in 27 % of patients.
Blindness was 0.05 % after treatment. Recurrence rate
was 14.5 %. In conclusion, ocular toxoplasmosis
substantially varies among patients with different
age, gender, site of lesion and other factors. Suddenly
blurred vision, floater, and pain could be caused by
Toxoplasma gondii. Flashing, may necessitate a more
precise peripheral fundus examination.
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Introduction
Toxoplasmosis is the most common cause of posterior
uveitis in the world and has the potential to cause
blindness and visual impairment in children and young
adults due to posterior segment abnormality [1].
Signs and symptoms of ocular toxoplasmosis vary
with age. Children are generally referred to an
ophthalmologist complaining of decreased visual
acuity, strabismus, nystagmus, leukocoria, choroidal
coloboma and microphthalmia [2].
The typical complaints in ocular toxoplasmosis, in
adolescents and adults, are blurred vision, floaters and
sometimes pain, and photophobia and conjunctival
hyperemia if the anterior segment is involved. The most
common cause of visual loss in ocular toxoplasmosis is
a macular scar, but causes of substantial visual loss in
ocular toxoplasmosis include dragging of the macula
secondary to peripheral lesion, retinal detachment,
macular edema, optic atrophy, cataract, glaucoma,
opacification of the media, amblyopia and phthisis.
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Evidence from clinic-based follow-up studies sug-
gests that retinochoroidal lesions occur in over 80 %
of people with congenital toxoplasmosis [3–5].
Despite years of extensive research, the develop-
ment of novel antitoxoplasmic drugs, and preventive
measures directed toward this ubiquitous infection,
many basic questions about ocular toxoplasmosis
remain unanswered, and curative therapy is not
available.
The purpose of this study was to determine in a
large series of patients the clinical features of ocular
toxoplasmosis infection and some complications of
ocular toxoplasmosis, and to introduce two new ones
not hitherto encountered in the literature, and, if
possible, to identify a profile of patients at risk of
visual loss. It was hoped that the result would be useful
for comparison with previous studies outside Iran.
Materials and methods
This study was a descriptive retrospective study. The
data were collected from the Uveitis Subdivision and
the Vitreo-retina Subdivision of Feiz Hospital medical
practice. We conducted a retrospective analysis of the
medical records of 1,000 consecutive patients with
uveitis who had consulted our department between
2003 and 2009, to identify patients with the diagnosis
of ocular toxoplasmosis. The study protocol was
reviewed and approved by the Clinical Research
Ethics Committee of the Iran University of Isfahan.
In this study we included 193 consecutive patients with
active lesions of ocular toxoplasmosis (first attack and/
or recurrence) and excluded eight patients with an
asymptomatic retinochoroidal scar compatible with
the diagnosis of ocular toxoplasmosis who were not
examined during the active stage of the disease.
Diagnosis was established by clinical characteristics
consistent with retinochoroiditis (foci of retinal necro-
sis), in the absence of other identifiable diseases, by
one ophthalmologist working in retina and vitreous,
and by laboratory examinations.
The clinical diagnosis of ocular toxoplasmosis was
based on criteria formulated by Holland et al. [6].
Active ocular toxoplasmosis was defined by the
presence of an active creamy-white focal retinal lesion
eventually resulting in hyperpigmented retinochoroi-
dal scars in either eye. Primary ocular toxoplasmosis
was defined as an active creamy-white focal retinal
lesion together with specific immunoglobulin (Ig)
M antibodies. Recurrent ocular toxoplasmosis was
defined as an active retinochoroidal lesion in the
presence of old pigmented retinochoroidal scars in
either eye. Central lesions were defined as lesions
located within the large vascular arcades. The labora-
tory examinations were IgG and IgM for toxoplasmo-
sis in patients’ blood sera.
Serological criteria for the acute phase of systemic
infection with Toxoplasma gondii included the pres-
ence of specific IgM antibodies. All patients with
primary lesions were examined for the presence of
IgM and for comparison purposes this assay was also
requested in some patients with recurrent lesions or in
the quiescent phase. The chronic phase of systemic
infection was defined as positive IgG antibodies
(any positive titer) without IgM antibodies. T. gondii
serology was performed routinely in all cases by
ELISA IgG and IgM commercial assays (Euroim-
mun). Congenital infection was defined by the pres-
ence of a positive PCR assay on amniotic fluid during
pregnancy or as ocular symptoms at birth accompa-
nied or not by neurological symptoms (micro- or
macrocephaly or cerebral calcifications) with a per-
sistent IgG anti-Toxoplasma at 12 months of life, and
acquired infection was defined in adults ([18 years of
age) with a specific IgM-positive test. Patients under
18 years of age and with IgM were considered to be of
uncertain origin because some patients with confirmed
congenital toxoplasmosis have persistent specific
IgM-positive tests up to 10 years of age [7].
For the purpose of this study, retinochoroidal
lesions were subdivided into three groups: smaller
than disc, equal to disc and larger than disc.
Patients with acquired immunodeficiency syn-
drome (AIDS) were excluded, because it may affect
clinical presentation of the disease. Chest X-ray,
fluorescent treponemal antibody, complete blood cell
count, C-reactive protein, erythrocyte sedimentation
rate, Lyme and Bartonella assays and purified protein
derivative (tuberculin) tests were performed in
patients without typical presentation.
Legal blindness was defined as the best-corrected
visual acuity of the affected eye equal to or less than
20/200 [8–10].
Visual outcome is given by the final optimal visual
acuity (not the worst visual acuity at any visit).
Data included age, sex, occupation, chief complaint,
visual acuity, clinical features, bilateral involvement,
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therapeutic outcome and complications. All of the
data were tabulated and analyzed descriptively and
statistically.
Data were analyzed by SPSS v.13 (SPSS Inc.,
Chicago, IL, USA). Chi-squared tests and t-tests
were used for the quantitative and qualitative data,
respectively. P \ 0.05 was considered statistically
significant.
Results
In the preceding 6 years, there were 193 ocular
toxoplasmosis cases, consisting of 82 (43 %) males
and 111 (57 %) females. The age range of patients at
first presentation to the ophthalmologist with an active
ocular toxoplasmosis lesion was 2–65 years with a
mean age of 24.6 years, but mostly in the 2nd and 3rd
decades (n = 104). The mean age was 23.4 years in
men and 25.1 years in women. Subclinical (quiet)
retinochoroidal scars in addition to active lesions were
observed in 177 of 193 patients (91.7 %) at the time of
first presentation with active ocular toxoplasmosis.
These old scars were located in the eye with the active
lesion (n = 130) and in the contralateral eye (n = 47).
No previous scars were observed in 16 of 193 (8.2 %)
patients. In 94.3 % (182) of the patients, ocular
toxoplasmosis became manifest before the age of
40 years (in 67.8 % between 15 and 35 years).
At the end of follow-up, bilateral disease was
present in 53 (27 %) patients. Patients with primary
ocular toxoplasmosis were older than those who were
first seen with a combination of active lesions and old
scars (P = 0.03). Acquired infection was documented
in 16 (8.2 %) patients and infection of uncertain origin
in 177 (91.7 %) patients.
Serological characteristics of the acute phase of
systemic infection were present in 35 (18.1 %)
patients. Serological characteristics of the chronic
phase of systemic infection were present in 158
(81.9 %) patients.
The presenting symptom was blurred vision in 181
patients (93.78 %), floater in 25 patients (13.4.0 %)
and pain in two patients (1.03 %) (Table 1).
Abnormality was commonly found in the poster-
ior segment, especially in the macular area. Sixteen
of the chorioretinitis cases were young adults,
19–23 years old, who were assumed to have acquired
toxoplasmosis; they had a history of fever, and
presented with regional lymphadenopathy.
Among the abnormalities that threatened vision
were neuroretinitis, papillitis, optic nerve atrophy,
macular scar and juxtapapillaris scar. Ocular mani-
festations of ocular toxoplasmosis are summarized in
Tables 2 and 3. In 124 patients (64.2 %) the retinal
lesion was central; 62 patients had a peripheral lesion
(32.1 %).
Associated clinical characteristics during attacks of
ocular toxoplasmosis are given in Table 4. Intraocular
inflammation was more severe in patients with
acquired or primary ocular toxoplasmosis and eight
patients had anterior uveitis without associated active
retinal lesions. Multiple active lesions, which occurred
simultaneously during the same attack, were noted in
22 patients.
Table 1 Chief complaints of ocular toxoplasmosis (193 cases)
Symptom(s) Total %
Blurred vision 184 96
Floaters 25 13.47
Pain 2 1.03
Table 2 Ocular toxoplasmosis manifestations in the posterior
segment (193 cases)
Clinical features Total %
Typical (retinitis on border of scar) 177 91.7
Atypical (retinitis without
scar)
Neuroretinitis 1 0.51
Papillitis 2 1.03
Retinitis without
scar
13 6.7
Table 3 Characteristics of retinal lesions in ocular toxoplas-
mosis (affected eyes) location of retinal lesions (n = 193 eyes)
Locatin Number %
Within vascular arcades (central) 124 64.2
Macular 98 50.7
Extramacular 26 13.5
Peripheral 62 32.1
Both central and peripheral 7 3.6
Extensive retinal lesions (larger than optic
disc diameters) at presentation
76 39.3
Macular 98 50.7
Adjacent to optic nerve other central location 13 6.7
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All patients received a specific therapy with
pyrimethamine, trisulfa or steroid. Improvement of
visual acuity occurred especially in acute or relapsed
cases and those involving the macula or optic nerve
papilla.
Of 193 ocular toxoplasmosis patients who were
followed for more than 5 years, 28 (14.5 %) devel-
oped one or more recurrences: 26 (92.8 %) patients
had one recurrence and two patients had two recur-
rences. Recurrent disease in both eyes developed in
two of 28 (7.1 %) patients. The percentage of patients
with recurrences increased with follow-up time.
Complications developed in 26 of 193 (13.47 %)
patients, whereby five (2.5 %) required at least one
(intra)ocular surgical procedure. Retinal detachment
occurred in 11 (5.69 %) patients. Pars plana detach-
ment occurred in one case and was treated with
cryopexy and prophylaxis. In three patients cystoid
macular edema was obvious on fundus slit lamp
examination during active attacks, and four patients
developed cellophane maculopathy and macular
pucker (Table 5).
Blindness in one eye developed in 19 of 193 (21 %)
patients before treatment and one eye became legally
blind after treatment. Legal blindness was caused
predominantly by the macular location of the retinal
lesion in 13 of 19 (68.4 %) patients, retinal detach-
ment in four (21 %) patients and optic nerve atrophy in
two (10.5 %) patients (Table 6).
Discussion
This study describes the clinical features and visual
outcome of ocular toxoplasmosis in a large series of
patients.
In our study, the mean age at first presentation with
symptomatic ocular toxoplasmosis was 24.6 years,
and 67.8 % of the cases became manifest between 15
and 35 years, which is similar to the mean age
reported previously [11, 12]. However, because qui-
escent subclinical retinochoroidal scars were already
present in most patients (177 of 193; 91.7 %) at
the time of the first clinical presentation with active
ocular toxoplasmosis, the exact age at onset of ocular
toxoplasmosis remains unknown for most patients.
The presence of inactive retinal scars at the time of
first presentation with active lesions has already been
noted [11, 13, 14].
As in previous studies [15, 16], elderly patients had
larger lesions. This was attributed to the possible decline
of cell-mediated immunity in the elderly [17, 18].
In our study, ocular toxoplasmosis was more
prevalent in females (57.0 %), which is similar to some
previous studies [15, 19]. The frequency of 18.1 % of a
positive IgM assay was lower than that reported
previously of 37 % for patients during the acute phase
of ocular toxoplasmosis in Iran by the highly-sensi-
tive assay ISAGA [20, 21]. This could be partly
explained by the different commercial assays used.
Table 4 Clinical characteristics of patients with ocular
toxoplasmosis
Total Number %
Anterior chamber reaction 73 37.8
Keratic precipitates 63 32.6
Fine keratic precipitates 55 28.49
Mutton fat keratic precipitates 8 4.1
Papillitis 2 1.03
Vitritis 191 98.9
Vascular sheatening 140 72.5
Vein and arterial sheatening 28 38.3
Arterial sheatening 74 38.3
Vein sheatening 38 19.6
Table 5 Ocular complications caused by congenital toxo-
plasmosis (n = 193)
Complications Total %
Regmatogenic retinal detachment 5 2.5
Serous retinal detachment 7 3.62
Vitreous hemorrhage 1 0.51
Pars plana detachment 1 0.51
Cystoid macular edema 3 1.55
Macular pucker 4 2.07
Large macular scar 4 2.07
Optic nerve atrophy 2 1.03
Table 6 Visual impact of ocular toxoplasmosis. Visual acuity
frequency (WHO criteria) (n = 193)
Vision n %
Good vision [7/10 100 51.8
Visual impairment (6/10–\20/200) 74 38.33
Blindness (\20/200) 19 9.8
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The exact location of the lesions in ocular toxo-
plasmosis was not reported in most of the previous
studies [11, 12, 22]. Macular lesions were found in
50.7 % of the patients, which is in agreement with
earlier studies [13, 23], and most patients (67.8 %) had
an ocular lesion in the posterior pole, which was in
agreement with other authors [24, 25].
We found papillitis (an atypical presentation of
ocular toxoplasmosis) in 1 % of cases, which is lower
than the 5 and 7 % reported in Turkey and Colombia
[7, 26].
Bilateral involvement in ocular toxoplasmosis
varies between 22 and 40 % [11, 14, 27–30], which
is consistent with the 27 % found in this series. If we
accept that bilateral involvement is more prevalent in
congenital cases, we can conclude that our series
includes a large number of acquired toxoplasmosis
cases [31].
The most common symptom was a decrease in
visual acuity (93.78 % of patients), caused by macular
lesion, optic papilla, juxtapapillaris, the presence of
vitreous cells and inflammation in the anterior seg-
ment [32].
Eight patients had anterior uveitis without associ-
ated active retinal lesions; all already had old retinal
scars. Anterior uveitis could be caused by the parasite
itself or because small chorioretinal lesions were not
detected at ophthalmoscopy [33, 34]. There were two
patients with chorioretinitis without frank vitritis
(1 %), which could be explained by a low inflamma-
tory reaction in these cases.
The 21 % frequency of definitive unilateral blind-
ness is similar to that reported in the Netherlands [35]
and is due to the macular location of the retinal lesions
and retinal detachment, which is consistent with the
literature [36, 37].
The most common complication found in ocular
toxoplasmosis was serous retinal detachment (3.6 %)
due to severe inflammatory reaction and lesions larger
than the optic disc, and could be managed with anti-
inflammatory agents. Other complications were vitreal
bleeding and epiretinal membrane but no phthisis
bulbi was found. Tractional ciliary body detachment
and associated hypotony is an uncommon complica-
tion of toxoplasmosis. One case with pars plana
detachment due to capsule contraction syndrome was
found, which has not been reported in other studies. It
has been associated with various eye diseases includ-
ing pseudoexfoliation, pars planitis, low grade vitritis,
high myopia, retinitis pigmentosa, and myotonic
dystrophy. Elevated intraocular pressure [36] was also
not noted in this study and the incidence of retinal
detachment was 2.5 %. Two patients had retinal
detachment and retinal tear in active ocular toxoplas-
mosis with severe intraocular inflammation and three
patients had retinal tear after inflammation recovery.
The impact on visual acuity of toxoplasmosis infec-
tion was significant and 100 cases (51.8 %) before
treatment and 136 cases (70.4 %) after treatment had
good vision, which means that almost 29.6 % of cases
had visual disturbances. The study showed that the
visual prognosis was worse for one patient after
treatment, and there were seven cases of non-rhegma-
togenous retinal detachment without surgical therapy.
The development of recurrent disease in our study
increased with follow-up time, being 14.5 % for those
followed for at least 6 years; most attacks occurred
between the ages of 15 and 45 years (mean age =
23.78). For that reason, routine examination every six
months during the vulnerable age is necessary. In the
literature, recurrence rates of 40–78 % were reported
[11, 27, 38, 39]. Short-term treatment with antipara-
sitic drugs may reduce the recurrence rates [40–44].
However, the follow-up time in these studies was
highly variable, which might explain the discrepancies
with our data. The presence of different T. gondii
strains associated with differences in pathogenicity
and sensitivity to therapies cannot be ruled out.
To summarize, nearly one quarter of our patients
with ocular toxoplasmosis developed legal blind-
ness in at least one eye, and 14.5 % of the patients
on long-term follow-up developed recurrences, which
occurred predominantly in eyes with old scars.
Despite the limitations of the retrospective nature of
this study, we have provided an up-to-date description
of the clinical manifestations, course, and prognosis of
ocular toxoplasmosis in a large series of patients.
These data might be of value when advising and
treating patients with this ocular infection and are
crucial for future prospective studies.
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